Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
MTP Midatech Pharma Plc daily Stock Chart
MTP [NASD]
Midatech Pharma Plc
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.85 Insider Own70.71% Shs Outstand61.08M Perf Week-22.40%
Market Cap9.48M Forward P/E- EPS next Y- Insider Trans- Shs Float26.97M Perf Month-16.78%
Income- PEG- EPS next Q- Inst Own- Short Float0.00% Perf Quarter-73.70%
Sales10.14M P/S0.93 EPS this Y- Inst Trans- Short Ratio0.00 Perf Half Y-77.73%
Book/sh1.01 P/B0.15 EPS next Y- ROA- Target Price- Perf Year-87.82%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.12 - 1.80 Perf YTD0.13%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-90.82% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low33.95% ATR0.03
Employees70 Current Ratio- Sales Q/Q16.10% Oper. Margin- RSI (14)42.13 Volatility14.19% 19.09%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.91 Prev Close0.16
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume265.03K Price0.17
Recom- SMA201.95% SMA50-31.46% SMA200-71.12% Volume184,049 Change6.44%
Dec-11-18 03:17AM  Heres What Münchener Tierpark Hellabrunn AGs (MUN:MTP) P/E Is Telling Us Simply Wall St. -14.53%
Oct-10-18 04:28AM  Why Münchener Tierpark Hellabrunn AG (MUN:MTP) Delivered An Inferior ROE Compared To The Industry Simply Wall St.
Oct-03-18 11:00AM  MTP: Converting to R&D Focused Company Through Divestiture of U.S. Commercial Arm Zacks Small Cap Research
Sep-27-18 07:00AM  Midatech Announces Proposed Sale of Midatech Pharma US Inc. (MTP US) to Kanwa Holdings, LP an affiliate of Barings LLC GlobeNewswire
Sep-18-18 06:36AM  Who Are Midatech Pharma Plcs (LON:MTPH) Major Shareholders? Simply Wall St.
Sep-07-18 10:30AM  MTP: Positive Interim Results for MTD201 Proof-of-Concept Study Zacks Small Cap Research -5.36%
Aug-31-18 07:00AM  Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera Microsphere Technology GlobeNewswire +29.11%
Jul-25-18 07:00AM  Midatech Pharma PLC: Trading Update GlobeNewswire -5.78%
Jul-23-18 09:23AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:11AM  Midatech Pharma US announces Co-Promotion Agreement with Bausch Health Companies Inc. for the Exclusive Right to Promote NeutraSal® to the Oncology Market in United States GlobeNewswire
Jun-08-18 02:00AM  Midatech Pharma US enrols first patient in Gelclair trial in stem cell transplant GlobeNewswire +9.88%
May-29-18 02:51PM  Tuesday's Market Sell-Off: The 52 Week Highs and Lows TheStreet.com
May-25-18 07:00AM  Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer GlobeNewswire
May-03-18 08:20AM  Todays Research Reports on Stocks to Watch: Midatech Pharma and Eleven Biotherapeutics ACCESSWIRE -14.19%
Apr-27-18 09:45AM  MTP: Midatech Targeting $2 Billion Market Opportunity with MTD201 Zacks Small Cap Research
Mar-23-18 03:32AM  Where Münchener Tierpark Hellabrunn AGs (MUN:MTP) Earnings Growth Stands Against Its Industry Simply Wall St.
Mar-15-18 08:01AM  Midatech announces changes in Senior Management Team GlobeNewswire +28.55%
Mar-07-18 10:15AM  MTP: Lead Candidates Set to Enter the Clinic; U.S. Product Sales Up ~30% in 2017 Zacks Small Cap Research
Feb-28-18 07:00AM  Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency GlobeNewswire
Feb-14-18 07:00AM  Midatech Pharma Plc: Trading update GlobeNewswire
Jan-16-18 07:01AM  Midatech and UCSF receive IND approval for DIPG treatment MTX110 GlobeNewswire
Jan-12-18 12:00PM  MTP: Receives Approval to Initiate First In Human Trial of Q-Octreotide (MTD201); Four Year Loan Agreement with MidCap Financial Zacks Small Cap Research
Nov-27-17 03:00PM  Initiating Coverage of Midatech Pharma (MTP); Novel Nanotechnology Platforms Focused on Oncology and Other Therapeutic Areas Zacks Small Cap Research -5.88%
Oct-27-17 01:59PM  Is Midatech Pharma Plc (AIM:MTPH) Undervalued? Simply Wall St. -6.08%
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer. Midatech Pharma PLC is collaborating with universities and pharmaceutical companies to develop its platform technologies into a range of products. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.
open in yahoo | open in reuters | open in google